Chronic fatigue syndrome treatment market to reach $3.07 billion by 2030
The chronic fatigue syndrome treatment market is projected to grow from $2.09 billion in 2025 to $2.26 billion in 2026, then reach $3.07 billion by 2030, according to The Business Research Company. The report points to rising use of non-drug approaches, broader clinical recognition, and expanding patient support as key growth drivers.
Why it matters: - The chronic fatigue syndrome treatment market is expanding as more patients seek care that focuses on symptom relief, energy improvement, and long-term quality of life. - The shift toward non-pharmacological care could change how hospitals, clinicians, and patients manage a condition with complex and persistent symptoms. - The market outlook signals stronger demand for multidisciplinary care, digital support tools, and personalized treatment plans.
What happened: - The Business Research Company released its Chronic Fatigue Syndrome Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on November 18, 2026. - The report says the market will grow from $2.09 billion in 2025 to $2.26 billion in 2026. - That forecast implies an 8.2% compound annual growth rate. - The market is expected to reach $3.07 billion by 2030, with a 7.9% compound annual growth rate over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow fastest during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The report offers a free sample and the full market report through the company’s website: free sample and the full report.
The details: - Greater clinical recognition of chronic fatigue syndrome is one of the main forces behind near-term growth. - Hospital-based fatigue management programs are also contributing to demand. - Increased use of antidepressants and sleep aids is supporting market expansion. - Broader acceptance of cognitive behavioral therapy is helping widen treatment options. - Higher patient advocacy and awareness are adding to market growth. - The report says intensified research into the biological causes of the syndrome will help support future expansion. - Rising demand for holistic and personalized care approaches is expected to lift adoption. - Digital health support tools are becoming part of treatment strategies. - Improving long-term quality of life is a key market focus. - Multidisciplinary treatment strategies are gaining traction. - The report identifies integrated treatment protocols, non-pharmacological therapies, enhanced symptom management programs, personalized treatment plans, and patient-centered care models as major trends. - Chronic fatigue syndrome treatment aims to manage persistent, unexplained fatigue while improving wellbeing and functional recovery.
Between the lines: - The report reflects a broader medical shift away from medication-only responses toward care models built around support, function, and risk reduction. - The emphasis on non-drug treatment suggests clinicians and health systems are treating chronic fatigue syndrome more as a long-term management challenge than a short-term symptom problem. - The UK National Health Service reported in May 2025 that 670,000 people received psychological therapies, including cognitive behavioral therapy, during 2023/24, underscoring wider adoption of behavioral care.
What's next: - Growth is likely to continue as researchers look more closely at the biological causes of chronic fatigue syndrome. - Treatment models are expected to become more personalized and more integrated across disciplines. - Digital health tools and non-drug therapies are likely to play a larger role in future care pathways. - The market report says updated graphics, forecasting dashboards, market attractiveness scoring, TAM analysis, company scoring matrices, and hotspot infographics are included in the 2026 edition.
The bottom line: - Chronic fatigue syndrome treatment is becoming a larger global market, with growth driven less by drug development and more by broader clinical recognition, non-pharmacological care, and patient-centered management.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
United Kingdom Globe Dispatch
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.